JP Morgan Initiates Coverage On Travere Therapeutics with Overweight Rating, Announces Price Target of $26
Portfolio Pulse from richadhand@benzinga.com
JP Morgan analyst Anupam Rama has initiated coverage on Travere Therapeutics (NASDAQ:TVTX) with an Overweight rating and a price target of $26.
July 21, 2023 | 9:01 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan has initiated coverage on Travere Therapeutics with an Overweight rating and a price target of $26, which could positively impact the stock.
The initiation of coverage by JP Morgan with an Overweight rating indicates a positive outlook for Travere Therapeutics. The price target of $26 suggests that the analyst believes the stock has significant upside potential. This could lead to increased investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100